MicroRNA Regulation of Osteoclast Differentiation and Function

Osteoclasts are specialised multinucleated cells responsible for bone resorption and play a central role in skeletal homeostasis. Their differentiation from mononuclear precursors is orchestrated by signalling pathways activated by macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL). MicroRNAs (miRNAs), a class of small non-coding RNAs, fine-tune this process by post-transcriptional repression of target mRNAs, thereby coordinating gene networks that govern precursor commitment, cell–cell fusion, cytoskeletal organisation and resorptive activity. Individual miRNAs exert stage-specific effects: some, such as miR-21 and miR-214, promote cytoskeletal remodelling and sealing-zone formation essential for bone matrix degradation, whereas others, including members of the miR-29 family, facilitate precursor migration and survival. Dysregulation of these miRNA circuits contributes to pathological bone loss in osteoporosis, inflammatory arthritis and tumour-induced osteolysis. Recent advances reveal that manipulating miRNA levels in vivo—either through genetic ablation, antagomir delivery or viral vectors—can restore the balance between bone formation and resorption. This highlights the therapeutic potential of miRNA-based strategies for skeletal disorders and underscores the need to map miRNA–mRNA interactomes in osteoclast lineage cells.

Research from Nature Portfolio

In vivo studies have demonstrated that deletion of miR-21 leads to a marked reduction in osteoclast activity, resulting in increased trabecular bone mass under both physiological and osteoporotic conditions. Loss of miR-21 impairs osteoclast resorption by upregulating its targets, including Sprouty1 and programmed cell death 4, thereby uncoupling RANKL-driven differentiation from bone degradation. Complementing this, osteoclast-specific overexpression of miR-214-3p has been shown to downregulate TRAF3, amplifying osteolytic responses in models of breast cancer metastasis to bone. Conversely, genetic ablation or targeted antagomir-mediated inhibition of miR-214-3p restores TRAF3 expression, attenuates osteoclast-mediated bone loss and offers a potential strategy to mitigate tumour-associated skeletal complications.

MicroRNA Regulation of Osteoclast Differentiation and Function publication trend

The graph below shows the total number of articles in microrna regulation of osteoclast differentiation and function across all publications each year (not limited to Nature Index journals).

Technical terms

microRNA (miRNA): Short, non-coding RNA molecules (~22 nucleotides) that bind target mRNAs to repress translation or induce degradation.

Osteoclastogenesis: The process by which mononuclear precursors differentiate into mature, multinucleated osteoclasts capable of bone resorption.

RANKL: Receptor activator of nuclear factor κB ligand, a cytokine essential for osteoclast differentiation and activation.

M-CSF: Macrophage-colony stimulating factor, a growth factor that promotes survival and proliferation of osteoclast precursors.

References

1. Concomitant induction of SLIT3 and microRNA-218–2 in macrophages by toll-like receptor 4 activation limits osteoclast commitment. Cell Communication and Signaling (2023).
2. miRNA-27a is essential for bone remodeling by modulating p62-mediated osteoclast signaling. eLife (2023).
3. Adenovirus-associated anti-miRNA-214 regulates bone metabolism and prevents local osteoporosis in rats. Frontiers in Bioengineering and Biotechnology (2023).
4. miR-21 deficiency inhibits osteoclast function and prevents bone loss in mice. Scientific Reports (2017).
5. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer. Scientific Reports (2017).
6. miR-29 Promotes Murine Osteoclastogenesis by Regulating Osteoclast Commitment and Migration*. Journal of Biological Chemistry (2013).